Skip to main content

Oramed Pharmaceuticals Inc.

ORMP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001176309

In the last 90 days, Oramed Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 84 institutions reported holding it in 13F filings for Q2 2026, worth $80.7M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Oramed Pharmaceuticals Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of ORMP: Q2 2023 compared with Q3 2023
MeasureQ2 2023Of which not filed for Q3 2023Q3 2023Change
Holders50256+8
Shares2.28M5.83K2.30M+24.4K (+1.1%)
Value$8.16M$20.4K$5.99M−$2.15M (−26.4%)

2 institutions that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (14)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to ORMP in Q3 2023
InstitutionSharesValue% of portfolio
Rathbone Brothers plc289,803$756.4K0.01%
Dimensional Fund Advisors LP27,285$71.2K0.00%
Virtu Financial LLC17,388$45.0K0.00%
Algert Global LLC14,680$38.3K0.00%
N.E.W. Advisory Services LLC12,960$33.8K0.00%
Wealth Enhancement Advisory Services, LLC11,900$31.1K0.00%
Group One Trading, L.P.10,495$27.4K0.00%
Invesco Ltd.10,094$26.3K0.00%
Qube Research & Technologies Ltd9,890$25.8K0.00%
Royal Bank of Canada5,273$14.0K0.00%
Quantbot Technologies LP931$2.43K0.00%
FMR LLC900$2.35K0.00%
Federated Hermes, Inc.122$3180.00%
BNP Paribas Arbitrage, SA13$340.00%

Sold out (6)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of ORMP in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Millennium Management LLC78,620$281.5K
Samson Rock Capital LLP36,856$131.9K
Acadian Asset Management LLC31,736$113.0K
Schonfeld Strategic Advisors LLC30,300$108.5K
Northern Trust Corp11,569$41.4K
HighTower Advisors, LLC10,500$39.0K

Not filed for Q3 2023 yet (2)

Institutions that held Oramed Pharmaceuticals Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ORMP in Q2 2023 that haven't filed for Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Endurance Wealth Management, Inc.5,700$20.0K
Coastal Capital Group, Inc.125$448